Jeffrey M. Leiden, Executive Chairman at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 145,384 shares at $440.22 ($64.1M) on 2025-11-13, disclosed to the SEC on 2025-11-17.
Scheduled sale ($64.1M) by Executive Chairman under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $440.22 | 18,528 | $8.2M | 12.7% |
| 2 | $440.22 | 18,528 | $8.2M | 12.7% |
| 3 | $441.05 | 1,160 | $512K | 0.8% |
| 4 | $440.30 | 32,234 | $14.2M | 22.2% |
| 5 | $440.30 | 32,234 | $14.2M | 22.2% |
| 6 | $441.35 | 21,330 |
| $9.4M |
| 14.7% |
| 7 | $441.35 | 21,330 | $9.4M | 14.7% |
| 8 | $442.00 | 40 | $18K | 0.0% |
| Total | $440.59 avg | 145,384 | $64.1M | 100% |
| Filing → |
| VRTX | SELL | 2024-09-04 | $1.9M | — | Filing → |
| VRTX | SELL | 2024-02-16 | $7.6M | — | Filing → |
| VRTX | SELL | 2024-02-14 | $2.8M | — | Filing → |